Muscle weakness and mitochondrial stress occur before metastasis in a novel mouse model of ovarian cancer cachexia
Authors: Delfinis Luca J. , Ogilvie Leslie M. , Khajehzadehshoushtar Shahrzad , Gandhi Shivam , Garibotti Madison C. , Thuhan Arshdeep K. , Matuszewska Kathy , Pereira Madison , Jones Ronald G. , Cheng Arthur J. , Hawke Thomas J. , Greene Nicholas P. , Murach Kevin A. , Simpson Jeremy A. , Petrik Jim , Perry Christopher G.R. 
Published: April 2024

AbstractObjectivesA high proportion of women with advanced epithelial ovarian cancer (EOC) experience weakness and cachexia. This relationship is associated with increased morbidity and mortality. EOC is the most lethal gynecological cancer, yet no preclinical cachexia model has demonstrated the combined hallmark features of metastasis, ascites development, muscle loss and weakness in adult immunocompetent mice.MethodsHere, we evaluated a new model of ovarian cancer-induced cachexia with the advantages of inducing cancer in adult immunocompetent C57BL/6J mice through orthotopic injections of EOC cells in the ovarian bursa. We characterized the development of metastasis, ascites, muscle atrophy, muscle weakness, markers of inflammation, and mitochondrial stress in the tibialis anterior (TA) and diaphragm ∼45, ∼75 and ∼90 days after EOC injection.ResultsPrimary ovarian tumour sizes were progressively larger at each time point while robust metastasis, ascites development, and reductions in body, fat and muscle weights occurred by 90 Days. There were no changes in certain inflammatory (TNFα), atrogene (MURF1 and Atrogin) or GDF15 markers within both muscles whereas IL-6 was increased at 45 and 90 Day groups in the diaphragm. TA weakness in 45 Day preceded atrophy and metastasis that were observed later (75 and 90 Day, respectively). The diaphragm demonstrated both weakness and atrophy in 45 Day. In both muscles, this pre-metastatic muscle weakness corresponded with considerable reprogramming of gene pathways related to mitochondrial bioenergetics as well as reduced functional measures of mitochondrial pyruvate oxidation and creatine-dependent ADP/ATP cycling as well as increased reactive oxygen species emission (hydrogen peroxide). Remarkably, muscle force per unit mass at 90 days was partially restored in the TA despite the presence of atrophy and metastasis. In contrast, the diaphragm demonstrated progressive weakness. At this advanced stage, mitochondrial pyruvate oxidation in both muscles exceeded control mice suggesting an apparent metabolic super-compensation corresponding with restored indices of creatine-dependent adenylate cycling.ConclusionThis mouse model demonstrates the concurrent development of cachexia and metastasis that occurs in women with EOC. The model provides physiologically relevant advantages of inducing tumour development within the ovarian bursa in immunocompetent adult mice. Moreover, the model reveals that muscle weakness in both TA and diaphragm precedes metastasis while weakness also precedes atrophy in the TA. An underlying mitochondrial bioenergetic stress corresponded with this early weakness. Collectively, these discoveries can direct new research towards the development of therapies that target pre-atrophy and pre-metastatic weakness during EOC in addition to therapies targeting cachexia.HighlightsThis study reports the first orthotopic model of metastatic ovarian cancer cachexia that can be induced in adult immunocompetent miceDiaphragm and limb muscle weakness precedes metastasis and atrophy during ovarian cancerSkeletal muscle mitochondrial oxidative and redox stress signatures occur during pre-metastatic stages of ovarian cancerSpecific muscle force as well as mitochondrial pyruvate oxidation and creatine metabolism demonstrate compensation in later stagesOvarian cancer has heterogeneous effects on distinct muscle types across time